1 / 8

Trial profile Data were censored at time of last follow-up for all participants

Trial profile Data were censored at time of last follow-up for all participants. The DREAM Trial Investigators Lancet 2006; 368: online. Baseline clinical and biochemical characteristics of participants. The DREAM Trial Investigators Lancet 2006; 368: online. Primary and other outcomes.

nelly
Download Presentation

Trial profile Data were censored at time of last follow-up for all participants

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial profile Data were censored at time of last follow-up for all participants The DREAM Trial Investigators Lancet 2006; 368: online

  2. Baseline clinical and biochemical characteristics of participants The DREAM Trial Investigators Lancet 2006; 368: online

  3. Primary and other outcomes The DREAM Trial Investigators Lancet 2006; 368: online

  4. Time to occurrence of primary outcome The DREAM Trial Investigators Lancet 2006; 368: online

  5. Effect of rosiglitazone on the primary outcome in key subgroups BMI=body-mass index IIFG=isolated impaired fasting glucoseIIGT=isolated impaired glucose tolerance WHR=waist-to-hip ratio The DREAM Trial Investigators Lancet 2006; 368: online

  6. Proportion of participants who either developed diabetes, regressed to normal, or had impaired fasting glucose or impaired glucose tolerance, or both, at the last assessment The DREAM Trial Investigators Lancet 2006; 368: online

  7. Effect of rosiglitazone on the point estimates of (A) fasting plasma glucose (FPG) and (B) 2-h plasma glucose (PG) concentrations The DREAM Trial Investigators Lancet 2006; 368: online

  8. The effect of rosiglitazone on weight and fat distribution The DREAM Trial Investigators Lancet 2006; 368: online

More Related